Rexahn names new CMO
This article was originally published in Scrip
Executive Summary
Rexahn Pharmaceuticals, a clinical stage biopharmaceutical company developing therapeutics for the treatment of cancer, has named Dr Ely Benaim chief medical officer. In this role, Dr Benaim will be responsible for leading Rexahn's clinical development programs, and providing strategic and clinical guidance for the company. Most recently Dr Benaim was senior vice-president of regulatory affairs and chief medical officer of Berg Pharma.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.